Brief: Alteogen receives U.S. patent
15/01/2018 02:33
Jan 15 (Reuters) - Alteogen Inc 196170.KQ :
* Says it received U.S. patent on Jan. 15, for highly
glycosylated
long-acting human growth hormone protein and production method
for same
Source text in Korean: https://goo.gl/xqwZp6
Further company coverage: 196170.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'